Hims & Hers

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income simplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 tipranks.com, and free cash flow turning positive in 2025 simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertainty simplywall.st. Key

3 November 2025

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Menopause Launch Sparks Surge in HIMS Stock Hims & Hers’ expansion into menopause care was greeted with enthusiasm in the market. On October 15, the San Francisco–based telehealth provider announced it is now offering affordable treatment plans for women in perimenopause and menopause via its Hers platform businesswire.com businesswire.com. The move adds a new specialty to Hers, which already serves over 500,000 women subscribers businesswire.com. By connecting patients with providers trained in menopause care, Hims & Hers aims to fill a long-neglected gap in women’s health. “Women have been navigating an outdated healthcare system that wasn’t designed for them for

17 October 2025

Health · Market Trends · Menopause · NYSE:HIMS · Pharmaceuticals · Weight Loss

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Stock Soars on New Menopause Care Expansion – What Comes Next?

Hims & Hers’ women’s health platform (Hers) now offers specialized menopause and perimenopause care investors.hims.com. The new service is aimed at improving access to hormone therapies (estradiol, progesterone, etc.) for symptoms like hot flashes and sleep issues, expanding a platform that already serves over 500,000 women. The October 15 jump in HIMS stock was driven by the menopause announcement. Investors saw the new specialty as a major driver of future growth, helping Hims & Hers address a long-ignored need in women’s health. As Benzinga reported, the stock closed the day up about 10–13% (trading near $60) after the news benzinga.com.

15 October 2025

Business News · Health Tech · Investment Trends · Menopause · NYSE:HIMS · Stock Market

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

“It’s never been more clear that we are delivering exactly what millions of people have been waiting for,” said HIMS CEO Andrew Dudum after Q2 results investors.hims.com. With analysts ranging from “Sell” to “Buy”, and social media buzzing, Hims & Hers remains one of 2025’s most talked-about healthcare stocks – its fortunes tightly tied to both the telehealth boom and regulatory oversight. Sources: Recent filings and press releases investors.hims.com investors.hims.com; Reuters and AP news on regulatory actions reuters.com reuters.com reuters.com; analyst reports and SEC filings quiverquant.com marketbeat.com; and HIMS-sponsored studies/news investors.hims.com fox10tv.com. (All figures as reported; analysis current as of

29 September 2025

FDA Regulation · Healthcare Stocks · Investment News · Market Trends · NYSE:HIMS · Stock Market · Weight Loss